Skip to main content
Saniona logo

Saniona — Investor Relations & Filings

Ticker · SANION ISIN · SE0005794617 LEI · 549300XO4L9XNOCFCZ84 ST Manufacturing
Open in API
Filings indexed 294 across all filing types
Latest filing 2025-04-02 Share Issue/Capital Cha…
Country SE Sweden
Listing ST SANION

About Saniona

http://saniona.com

Saniona is a clinical-stage biopharmaceutical company focused on the research and development of treatments for neurological disorders, with a primary emphasis on epilepsy. The company is a leader in the field of ion channel modulation, leveraging its expertise and a proprietary drug discovery engine to create new medicines. Saniona has developed an extensive library of over 20,000 proprietary molecules designed to target various ion channels. Its pipeline includes multiple potential new medicines advancing through clinical trials, with the goal of addressing unmet medical needs for patients with central nervous system diseases.

Recent filings

Filing Released Lang Actions
Saniona meddelar preliminärt utfall för nyttjandet av teckningsoptioner serie TO 4
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Saniona AB announcing the preliminary outcome of the exercise of warrants (series TO 4). It details the number of warrants exercised, the resulting new shares, and the financial impact (MSEK). This falls under the category of capital changes and share issues resulting from warrant exercises. While it mentions a future final report, the document itself is a direct announcement of a capital-related event, fitting the 'Share Issue/Capital Change' category.
2025-04-02 Swedish
Declaration of Voting Results & Voting Rights Announcements 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding ('Innehavare', 'Transaktionen', 'Efter transaktionen') for a specific instrument ('Aktie SE0005794617') involving an entity ('Nordnet AB (publ)'). The structure, including 'Gränsvärde' (threshold), 'Andel' (share percentage), and the reporting date, strongly indicates a mandatory disclosure regarding insider or significant ownership changes. This aligns perfectly with the definition of Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since the document explicitly tracks the percentage of shares held crossing a threshold (5%) and details the resulting ownership structure, it is a notification of a change in significant share ownership. Therefore, MRQ (Major Shareholding Notification) is the most appropriate classification.
2025-03-05 Swedish
Acadia Pharmaceuticals och Saniona meddelar initiala positiva resultat från fas 1-studien med ACP-711 (tidigare SAN711)
Legal Proceedings Report Classification · 99% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces initial positive results from a Phase 1 clinical study for a drug candidate (ACP-711). It contains forward-looking statements and contact information typical of a corporate announcement. Crucially, at the end, it lists "Bifogade filer" (Attached files) which are links to the full document/report. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA). This press release serves as the announcement vehicle for the study results, which would likely be detailed in a more comprehensive filing (like an IR or ER, but this is just the announcement). Therefore, RPA is the most appropriate classification.
2025-03-03 Swedish
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and announces initial positive results from a Phase 1 clinical study for a drug candidate (ACP-711). This format, focusing on immediate, material, non-financial operational news (clinical trial results), strongly aligns with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing key operational/clinical milestones rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT), it fits best as an Earnings Release (ER) if it were quarterly/annual results, or RNS if it's a general announcement. Given the context of clinical trial updates, which often accompany or substitute for earnings highlights in biotech, and the fact that it is a formal announcement of results, ER is a strong candidate. However, since it is not explicitly tied to a standard quarterly/annual reporting period but rather a specific clinical milestone, and it is a general announcement of material information, the most appropriate general category for immediate, non-standardized regulatory news is RNS (Regulatory Filings/General Announcement). The document length is moderate (7844 chars), and it does not primarily announce the *publication* of another document, but rather the *content* of the news itself. Given the options, ER covers immediate results announcements, but RNS is the safest catch-all for material press releases that aren't explicitly defined elsewhere. Since it details clinical trial progress and safety findings, which are material, I will classify it as an Earnings Release (ER) as these types of announcements often serve the function of providing immediate operational performance updates, similar to how earnings releases function for financial performance updates. If ER is too specific to financial results, RNS is the fallback. Given the structure, ER is often used for significant operational updates in pharma/biotech press releases.
2025-03-03 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding ('Köp' - Purchase) by an entity ('Nordnet AB (publ)') in another company ('Saniona AB'). It specifies the number of shares, the resulting percentage ownership (5.00646%), and the date of the transaction (2025-02-28). This structure, focusing on insider or major shareholder transactions crossing a threshold (5%), directly corresponds to the definition of Director's Dealing or Major Shareholding Notification. Since the transaction is by a major shareholder (Nordnet) crossing the 5% threshold, and the content is a formal notification of this change, it aligns best with 'Major Shareholding Notification' (MRQ) or 'Director's Dealing' (DIRS). Given that Nordnet is a large institutional holder and this is a notification of crossing a significant ownership threshold, MRQ is highly appropriate. However, DIRS often covers all insider/major shareholder transactions. Reviewing the definitions, DIRS is for 'Report of personal share transactions by company directors and executives (insider trades)'. MRQ is for 'Notification of changes in significant share ownership levels (crossing thresholds)'. Since this explicitly details crossing the 5% threshold, MRQ is the most precise fit, although DIRS is also plausible if the definition of 'director' is interpreted broadly to include major shareholders reporting transactions. Given the explicit mention of the 5% threshold crossing, MRQ is selected.
2025-03-03 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the period ending December 31, 2024. It includes detailed financial tables (Q4 and full-year results), a CEO letter, operational highlights, pipeline updates, and forward-looking statements. It is clearly a periodic financial report (Interim/Quarterly Report) rather than an announcement or a summary, as it contains substantive financial data and analysis. Q4 2024
2025-02-27 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.